|
GSK PLC on Wednesday said it has launched the tender offer for its previously announced acquisition of US-based cancer drug developer Nuvalent Inc for $10.6 billion. The London-based pharmaceutical manufacturer said it has launched a tender offer for $124.00 per Nuvalent share. The tender offer is at a roughly 40% premium to Nuvalent’s closing price in New York before the acquisition was first announced earlier in June. As soon as possible after the offer, Nuvalent will become a direct wholly-owned subsidiary of GSK. This marks the London-based pharmaceutical maker’s largest acquisition since 2014, when it bought Swiss peer Novartis AG’s vaccines business of $20 billion. The offer and withdrawal rights will expire at one minute after 1159 ET on July 14, GSK said. Shares in GSK were up 0.4% at 1,966.00 pence on Wednesday afternoon in London. Nuvalent shares were slightly higher at $123.50 in New York. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
